FDA
-
-
-
-
-
-
-
FDA advisory panel votes 10-3 in favor of Replimune's melanoma drug
-
-
-
-
-
-
-
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
-
-
-
-
-
-
-
FDA Commissioner Marty Makary is resigning - Politico reporter on X
-
-
-
-
-
-
-
Cantor Fitzgerald Downgrades Replimune Group (REPL) to Neutral
-
-
-
-
-
-
-
Replimune Reports Fiscal Second Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Replimune Highlights Acral Melanoma Data for RP1 plus Nivolumab at the ESMO Congress 2025
-
-
-
-
-
-
-
Replimune Group (REPL) PT Lowered to $8 at Jefferies
-
327,748 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

